Literature DB >> 15466380

Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.

Susana Aguilar1, Josep M Corominas, Núria Malats, José A Pereira, Marlène Dufresne, Francisco X Real, Pilar Navarro.   

Abstract

Tissue plasminogen activator (tPA) is absent from normal human pancreas and is expressed in 95% of human pancreatic adenocarcinomas. We have analyzed the expression of components of the tPA system in murine pancreatic tumors and the role of tPA in neoplastic progression. Transgenic mice expressing T antigen and c-myc under the control of the elastase promoter (Ela1-TAg and Ela1-myc, respectively) were used. tPA was undetectable in normal pancreas, acinar dysplasia, ductal complexes, and in all acinar tumors. By contrast, it was consistently detected in Ela1-myc tumors showing ductal differentiation. Crossing transgenic Ela1-myc with tPA-/- mice had no effect on the proportion of ductal tumors, indicating that tPA is not involved in the acinar-to-ductal transition. Ela1-myc:tPA-/- mice showed an increased survival in comparison to control mice. All ductal tumors, and none of the acinar tumors, overexpressed the tPA receptor annexin A2, suggesting its participation in the effects mediated by tPA. Our findings indicate that murine and human pancreatic ductal tumors share molecular alterations in the tPA system that may play a role in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466380      PMCID: PMC1618622          DOI: 10.1016/S0002-9440(10)63374-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Annexin II: a mediator of the plasmin/plasminogen activator system.

Authors:  K A Hajjar; S Krishnan
Journal:  Trends Cardiovasc Med       Date:  1999-07       Impact factor: 6.677

3.  A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease.

Authors:  M Wagner; F R Greten; C K Weber; S Koschnick; T Mattfeldt; W Deppert; H Kern; G Adler; R M Schmid
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

Review 4.  The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.

Authors:  N Bardeesy; N E Sharpless; R A DePinho; G Merlino
Journal:  Semin Cancer Biol       Date:  2001-06       Impact factor: 15.707

5.  Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha.

Authors:  S Y Song; M Gannon; M K Washington; C R Scoggins; I M Meszoely; J R Goldenring; C R Marino; E P Sandgren; R J Coffey; C V Wright; S D Leach
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

Review 6.  Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth.

Authors:  L Ossowski; J A Aguirre-Ghiso
Journal:  Curr Opin Cell Biol       Date:  2000-10       Impact factor: 8.382

Review 7.  Viewpoint: are studies in genetically altered mice out of control?

Authors:  C D Sigmund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

8.  p53-dependent acinar cell apoptosis triggers epithelial proliferation in duct-ligated murine pancreas.

Authors:  C R Scoggins; I M Meszoely; M Wada; A L Means; L Yang; S D Leach
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-10       Impact factor: 4.052

9.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.

Authors:  P Carmeliet; L Moons; R Lijnen; M Baes; V Lemaître; P Tipping; A Drew; Y Eeckhout; S Shapiro; F Lupu; D Collen
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

10.  Role of the basic helix-loop-helix transcription factor p48 in the differentiation phenotype of exocrine pancreas cancer cells.

Authors:  T Adell; A Gómez-Cuadrado; A Skoudy; O S Pettengill; D S Longnecker; F X Real
Journal:  Cell Growth Differ       Date:  2000-03
View more
  11 in total

Review 1.  Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.

Authors:  Anouchka Skoudy; Inmaculada Hernández-Muñoz; Pilar Navarro
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 2.  Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.

Authors:  J D Liao; N V Adsay; F Khannani; D Grignon; A Thakur; F H Sarkar
Journal:  Histol Histopathol       Date:  2007-06       Impact factor: 2.303

3.  Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.

Authors:  Elena Ortiz-Zapater; Sandra Peiró; Oriol Roda; Josep M Corominas; Susana Aguilar; Coral Ampurdanés; Francisco X Real; Pilar Navarro
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

4.  FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours.

Authors:  Ibane Abasolo; Judit Pujal; Rosa M Rabanal; Anna Serafin; Pilar Navarro; Olga Millán; Francisco X Real
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-28       Impact factor: 9.236

5.  Key contribution of CPEB4-mediated translational control to cancer progression.

Authors:  Elena Ortiz-Zapater; David Pineda; Neus Martínez-Bosch; Gonzalo Fernández-Miranda; Mar Iglesias; Francesc Alameda; Mireia Moreno; Carolina Eliscovich; Eduardo Eyras; Francisco X Real; Raúl Méndez; Pilar Navarro
Journal:  Nat Med       Date:  2011-12-04       Impact factor: 53.440

6.  Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice.

Authors:  Dezhong Joshua Liao; Yong Wang; Jiusheng Wu; Nazmi Volkan Adsay; David Grignon; Fayyaz Khanani; Fazlul H Sarkar
Journal:  J Carcinog       Date:  2006-07-05

7.  BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis.

Authors:  Laia Richart; Enrique Carrillo-de Santa Pau; Ana Río-Machín; Mónica P de Andrés; Juan C Cigudosa; Víctor J Sánchez-Arévalo Lobo; Francisco X Real
Journal:  Nat Commun       Date:  2016-01-05       Impact factor: 14.919

8.  S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility.

Authors:  T Nedjadi; N Kitteringham; F Campbell; R E Jenkins; B K Park; P Navarro; F Ashcroft; A Tepikin; J P Neoptolemos; E Costello
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

9.  Zinc-triggered induction of tissue plasminogen activator and plasminogen in endothelial cells and pericytes.

Authors:  Mun-Kyung Cho; Eun-Sun Sun; Yang-Hee Kim
Journal:  Exp Neurobiol       Date:  2013-12-31       Impact factor: 3.261

10.  Snail1 is required for the maintenance of the pancreatic acinar phenotype.

Authors:  Jordina Loubat-Casanovas; Raúl Peña; Núria Gonzàlez; Lorena Alba-Castellón; Santi Rosell; Clara Francí; Pilar Navarro; Antonio García de Herreros
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.